Clinical Trial Update: Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and tolerability of a PARP inhibitor in combination with carboplatin and/or paclitaxel in patients with triple-negative meta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• PARP inhibitor

Snippet

Sponsor: AstraZeneca | Conditions: Triple Negative Metastatic Breast Cancer, Advanced Ovarian Cancer | Phase 1 | Status: COMPLETED